Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14581370 | 0.87 | CA12 (0.68) | CA12CA9ALOX15HSD17B10CYP1A2 | |
| SCHEMBL45104 | 0.79 | HTR5A (0.53) | CA12CA9ALOX15HSD17B10GAA | |
| SCHEMBL89023 | 0.77 | ALOX15 (0.56) | CA12CA9ALOX15HSD17B10CYP1A2 | |
| SCHEMBL23615628 | 0.75 | CA12 (0.70) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL518841 | 0.75 | CA12 (0.44) | CA12CA9ALOX15HSD17B10CYP1A2 | |
| SCHEMBL29546699 | 0.75 | CA12 (0.44) | CA12CA9ALOX15HSD17B10CYP1A2 | |
| SCHEMBL2062062 | 0.75 | NPC1 (0.52) | CA12CA9ALOX15HSD17B10PNMT | |
| SCHEMBL820510 | 0.74 | PARP11 (0.59) | CA12CA9CYP1A2PNMTCD44 | |
| SCHEMBL6629246 | 0.74 | CA12 (0.47) | CA12CA9ALOX15HSD17B10CYP1A2 | |
| SCHEMBL8558277 | 0.72 | ALOX15 (0.50) | CA12CA9ALOX15HSD17B10PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121752551-A | Process for the preparation of 1, 5-dihydro-2, 4-benzodiazepine-3-one derivatives and intermediates thereof and process for the preparation thereof | 江苏恩华药业股份有限公司 | 2026-03-27 | — | — | CN | disclosed |
| EP-4700019-A1 | CRYSTAL FORM OF 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE CITRATE, PREPARATION METHOD, AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-02-25 | — | — | EP | disclosed |
| CN-121039114-A | Crystal forms of 1, 5-dihydro-2, 4-benzodiazepine-3-one derivative citrate, preparation method and application thereof | 江苏恩华药业股份有限公司 | 2025-11-28 | — | — | CN | disclosed |
| EP-4144725-B1 | 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF | JIANGSU NHWA PHARMACEUTICAL CO LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4144725-C0 | 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF | JIANGSU NHWA PHARMACEUTICAL CO LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| CN-116444484-B | Salts of 1, 5-dihydro-2, 4-benzodiazepine-3-one derivatives and uses thereof | 江苏恩华药业股份有限公司 | 2025-07-15 | — | — | CN | disclosed |
| WO-2025044768-A1 | PREPARATION METHOD FOR 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE, INTERMEDIATE THEREFOR, AND PREPARATION METHOD FOR INTERMEDIATE | 江苏恩华药业股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024217521-A1 | CRYSTAL FORM OF 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE CITRATE, PREPARATION METHOD, AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-115667236-B | 1, 5-Dihydro-2, 4-benzodiazepine-3-one derivative and application thereof | 江苏恩华药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-115667236-B | 1, 5-Dihydro-2, 4-benzodiazepine-3-one derivative and application thereof | 江苏恩华药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | CA12 2654/4885CA9 2692/4885ALOX15 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.